Literature DB >> 4204799

Isoniazid chemoprophylaxis of latent primary tuberculosis: in five trial centres in France from 1959 to 1969.

R Debre, S Perdrizet, A Lotte, M Naveau, F Lert.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1973        PMID： 4204799     DOI： 10.1093/ije/2.2.153

Source DB:  PubMed          Journal:  Int J Epidemiol        ISSN： 0300-5771            Impact factor:   7.196


× No keyword cloud information.
  7 in total

Review 1.  Anti-tuberculosis treatment strategies and drug development: challenges and priorities.

Authors:  Véronique A Dartois; Eric J Rubin
Journal:  Nat Rev Microbiol       Date:  2022-04-27       Impact factor: 78.297

Review 2.  Isoniazid preventive therapy and risk for resistant tuberculosis.

Authors:  Maria Elvira Balcells; Sara L Thomas; Peter Godfrey-Faussett; Alison D Grant
Journal:  Emerg Infect Dis       Date:  2006-05       Impact factor: 6.883

Review 3.  Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analyses.

Authors:  Christopher Pease; Brian Hutton; Fatemeh Yazdi; Dianna Wolfe; Candyce Hamel; Pauline Quach; Becky Skidmore; David Moher; Gonzalo G Alvarez
Journal:  BMC Infect Dis       Date:  2017-04-11       Impact factor: 3.090

4.  Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020.

Authors:  Timothy R Sterling; Gibril Njie; Dominik Zenner; David L Cohn; Randall Reves; Amina Ahmed; Dick Menzies; C Robert Horsburgh; Charles M Crane; Marcos Burgos; Philip LoBue; Carla A Winston; Robert Belknap
Journal:  MMWR Recomm Rep       Date:  2020-02-14

5.  Risk of developing active tuberculosis following tuberculosis screening and preventive therapy for Tibetan refugee children and adolescents in India: An impact assessment.

Authors:  Kunchok Dorjee; Sonam Topgyal; Tenzin Tsewang; Tenzin Tsundue; Tenzin Namdon; Elizabeth Bonomo; Caroline Kensler; Dekyi Lhadon; Tsering Choetso; Tenzin Nangsel; Tsering Dolkar; Thupten Tsekyi; Chungdak Dorjee; Dawa Phunkyi; Tsetan D Sadutshang; Zorba Paster; Richard E Chaisson
Journal:  PLoS Med       Date:  2021-01-19       Impact factor: 11.069

6.  Isoniazid or rifampicin preventive therapy with and without screening for subclinical TB: a modeling analysis.

Authors:  Emily A Kendall; Hamidah Hussain; Amber Kunkel; Rachel W Kubiak; Anete Trajman; Richard Menzies; Paul K Drain
Journal:  BMC Med       Date:  2021-12-14       Impact factor: 11.150

7.  Efficacy of isoniazid prophylactic therapy in prevention of tuberculosis in children: a meta-analysis.

Authors:  James Ayieko; Lisa Abuogi; Brett Simchowitz; Elizabeth A Bukusi; Allan H Smith; Arthur Reingold
Journal:  BMC Infect Dis       Date:  2014-02-20       Impact factor: 3.090
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.